Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 164
Filter
Add more filters

Publication year range
1.
Int J Mol Sci ; 22(3)2021 Jan 27.
Article in English | MEDLINE | ID: mdl-33513799

ABSTRACT

The Mediterranean diet (MD) is a combination of foods mainly rich in antioxidants and anti-inflammatory nutrients that have been shown to have many health-enhancing effects. Extra-virgin olive oil (EVOO) is an important component of the MD. The importance of EVOO can be attributed to phenolic compounds, represented by phenolic alcohols, hydroxytyrosol, and tyrosol, and to secoiridoids, which include oleocanthal, oleacein, oleuropein, and ligstroside (along with the aglycone and glycosidic derivatives of the latter two). Each secoiridoid has been studied and characterized, and their effects on human health have been documented by several studies. Secoiridoids have antioxidant, anti-inflammatory, and anti-proliferative properties and, therefore, exhibit anti-cancer activity. This review summarizes the most recent findings regarding the pharmacological properties, molecular targets, and action mechanisms of secoiridoids, focusing attention on their preventive and anti-cancer activities. It provides a critical analysis of preclinical, in vitro and in vivo, studies of these natural bioactive compounds used as agents against various human cancers. The prospects for their possible use in human cancer prevention and treatment is also discussed.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Antineoplastic Agents/pharmacology , Antioxidants/pharmacology , Iridoids/pharmacology , Neoplasms/prevention & control , Olive Oil/analysis , Aldehydes/chemistry , Aldehydes/pharmacology , Aldehydes/therapeutic use , Animals , Anti-Inflammatory Agents/therapeutic use , Antineoplastic Agents/therapeutic use , Antioxidants/therapeutic use , Cyclopentane Monoterpenes/chemistry , Cyclopentane Monoterpenes/pharmacology , Cyclopentane Monoterpenes/therapeutic use , Diet, Mediterranean , Glucosides/chemistry , Glucosides/pharmacology , Glucosides/therapeutic use , Humans , Iridoid Glucosides , Iridoids/chemistry , Iridoids/isolation & purification , Iridoids/therapeutic use , Neoplasms/diet therapy , Olive Oil/pharmacology , Phenols/chemistry , Phenols/pharmacology , Phenols/therapeutic use , Phenylethyl Alcohol/analogs & derivatives , Phenylethyl Alcohol/chemistry , Phenylethyl Alcohol/pharmacology , Phenylethyl Alcohol/therapeutic use , Pyrans/chemistry , Pyrans/pharmacology , Pyrans/therapeutic use
2.
Pharmacol Res ; 155: 104680, 2020 05.
Article in English | MEDLINE | ID: mdl-32032665

ABSTRACT

Friedreich's ataxia (FA) is due to deficiency of the mitochondrial protein, frataxin, which results in multiple pathologies including a deadly, hypertrophic cardiomyopathy. Frataxin loss leads to deleterious accumulations of redox-active, mitochondrial iron, and suppressed mitochondrial bioenergetics. Hence, there is an urgent need to develop innovative pharmaceuticals. Herein, the activity of the novel compound, 6-methoxy-2-salicylaldehyde nicotinoyl hydrazone (SNH6), was assessed in vivo using the well-characterized muscle creatine kinase (MCK) conditional frataxin knockout (KO) mouse model of FA. The design of SNH6 incorporated a dual-mechanism mediating: (1) NAD+-supplementation to restore cardiac bioenergetics; and (2) iron chelation to remove toxic mitochondrial iron. In these studies, MCK wild-type (WT) and KO mice were treated for 4-weeks from the asymptomatic age of 4.5-weeks to 8.5-weeks of age, where the mouse displays an overt cardiomyopathy. SNH6-treatment significantly elevated NAD+ and markedly increased NAD+ consumption in WT and KO hearts. In SNH6-treated KO mice, nuclear Sirt1 activity was also significantly increased together with the NAD+-metabolic product, nicotinamide (NAM). Therefore, NAD+-supplementation by SNH6 aided mitochondrial function and cardiac bioenergetics. SNH6 also chelated iron in cultured cardiac cells and also removed iron-loading in vivo from the MCK KO heart. Despite its dual beneficial properties of supplementing NAD+ and chelating iron, SNH6 did not mitigate cardiomyopathy development in the MCK KO mouse. Collectively, SNH6 is an innovative therapeutic with marked pharmacological efficacy, which successfully enhanced cardiac NAD+ and nuclear Sirt1 activity and reduced cardiac iron-loading in MCK KO mice. No other pharmaceutical yet designed exhibits both these effective pharmacological properties.


Subject(s)
Aldehydes/therapeutic use , Cardiomyopathies/drug therapy , Friedreich Ataxia/drug therapy , Hydrazones/therapeutic use , Iron Chelating Agents/therapeutic use , NAD/metabolism , Adenosine Triphosphate/metabolism , Aldehydes/pharmacology , Animals , Cardiomyopathies/metabolism , Cell Line , Creatine Kinase, MM Form/genetics , Disease Models, Animal , Friedreich Ataxia/metabolism , Hydrazones/pharmacology , Iron/metabolism , Iron Chelating Agents/pharmacology , Iron-Binding Proteins/genetics , Mice, Inbred C57BL , Mice, Knockout , Mitochondria, Heart/drug effects , Mitochondria, Heart/metabolism , Rats , Frataxin
3.
Phytother Res ; 34(11): 2820-2834, 2020 Nov.
Article in English | MEDLINE | ID: mdl-32449241

ABSTRACT

Cancer is among the leading causes of mortality worldwide. Current cancer therapies are associated with serious side effects, which further damage patients' health. Therefore, the search for new anticancer agents with no toxic effects on normal and healthy cells is of great interest. Recently, we and other groups have demonstrated that oleocanthal (OLC), a phenolic compound from extra virgin olive oil, exhibits antitumor activity in various tumor models. However, the underlying mechanisms and intracellular targets of OLC remain to be completely elucidated. This review summarizes the current advancers concerning the anticancer activity of OLC, with particular emphasis on the molecular signaling pathways modulated by this compound in different tumor cell types. The major mechanisms of action of OLC include modulation of the apoptotic pathway, the HGF/c-Met pathway, and the signal transducer and activator of transcription 3 signaling pathway, among others. Furthermore, OLC has synergistic effects with anticancer drugs in vitro. Also discussed are OLC bioavailability and its concentration in olive oil. Data summarized here will represent a database for more extensive studies aimed at providing information on molecular mechanisms against cancer induced by OLC.


Subject(s)
Aldehydes/therapeutic use , Antineoplastic Agents/therapeutic use , Cyclopentane Monoterpenes/therapeutic use , Neoplasms/drug therapy , Olive Oil/therapeutic use , Phenols/therapeutic use , Aldehydes/pharmacology , Antineoplastic Agents/pharmacology , Cyclopentane Monoterpenes/pharmacology , Humans , Olive Oil/pharmacology , Phenols/pharmacology , Signal Transduction/drug effects
4.
Phytother Res ; 33(1): 214-223, 2019 Jan.
Article in English | MEDLINE | ID: mdl-30375049

ABSTRACT

Cardiac fibrosis contributes to both systolic and diastolic dysfunction in many cardiac pathophysiologic conditions. Antifibrotic therapies are likely to be a crucial strategy in curbing many fibrosis-related cardiac diseases. In our previous study, an ethyl acetate extract of a traditional Chinese medicine Aristolochia yunnanensis Franch. was found to have a therapeutic effect on myocardial fibrosis in vitro and in vivo. However, the exact chemicals and their mechanisms responsible for the activity of the crude extract have not been illustrated yet. In the current study, 10 sesquiterpenoids (1-10) were isolated from the active extract, and their antifibrotic effects were systematically evaluated in transforming growth factor ß 1 (TGFß1)-stimulated cardiac fibroblasts and NIH3T3 fibrosis models. (+)-Isobicyclogermacrenal (1) and spathulenol (2) were identified as the main active components, being more potent than the well-known natural antifibrotic agent oxymatrine. Compounds 1 and 2 could inhibit the TGFß1-induced cardiac fibroblasts proliferation and suppress the expression of the fibrosis biomarkers fibronectin and α-smooth muscle actin via down-regulation of their mRNA levels. The mechanism study revealed that 1 and 2 could inhibit the phosphorylation of TGFß type I receptor, leading to the decrease of the phosphorylation levels of downstream Smad2/3, then consequently blocking the nuclear translocation of Smad2/3 in the TGFß/Smad signaling pathway. These findings suggest that 1 and 2 may serve as promising natural leads for the development of anticardiac fibrosis drugs.


Subject(s)
Aldehydes/therapeutic use , Aristolochia/chemistry , Fibrosis/drug therapy , Medicine, Chinese Traditional/methods , Sesquiterpenes/therapeutic use , Transforming Growth Factor beta/metabolism , Aldehydes/pharmacology , Animals , Fibrosis/pathology , Humans , Male , Mice , Mothers , Rats, Sprague-Dawley , Sesquiterpenes/pharmacology , Signal Transduction
5.
Int J Mol Sci ; 19(10)2018 Sep 24.
Article in English | MEDLINE | ID: mdl-30250008

ABSTRACT

The broad number of health benefits which can be obtained from the long-term consumption of olive oil are attributed mainly to its phenolic fraction. Many olive oil phenolics have been studied deeply since their discovery due to their bioactivity properties, such as Hydroxytyrosol. Similarly, in the last decade, the special attention of researchers has been addressed to Oleocanthal (OC). This olive oil phenolic compound has recently emerged as a potential therapeutic agent against a variety of diseases, including cancer, inflammation, and neurodegenerative and cardiovascular diseases. Recently, different underlying mechanisms of OC against these diseases have been explored. This review summarizes the current literature on OC to date, and focuses on its promising bioactivities against different disease-targets.


Subject(s)
Aldehydes/therapeutic use , Biological Products/therapeutic use , Cardiovascular Diseases/drug therapy , Inflammation/drug therapy , Neoplasms/drug therapy , Neurodegenerative Diseases/drug therapy , Olive Oil/chemistry , Phenols/therapeutic use , Cyclopentane Monoterpenes , Humans
6.
Am J Physiol Cell Physiol ; 311(4): C537-C543, 2016 Oct 01.
Article in English | MEDLINE | ID: mdl-27385721

ABSTRACT

In this perspective, we summarize and discuss critical advancements in the study of 4-hydroxy-2-nonenal (4-HNE) as it relates to diseases and clinical complications either caused or exacerbated by oxidative stress. Since its identification in 1980, 4-HNE has been extensively studied with an emphasis on its formation, its role in pathology, and its targets. As a reactive aldehyde, and a product of lipid peroxidation, studies corroborate its ability to disrupt signal transduction and protein activity, as well as induce inflammation and trigger cellular apoptosis in conditions of oxidative stress. Notably, we discuss the role of natural enzymes involved in the regulation of 4-HNE, and how they can be applied to its detoxification in various physiological conditions.


Subject(s)
Aldehydes/pharmacology , Aldehydes/therapeutic use , Oxidative Stress/drug effects , Animals , Apoptosis/drug effects , Humans , Lipid Peroxidation/drug effects , Signal Transduction/drug effects
7.
Tumour Biol ; 37(2): 1817-24, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26318300

ABSTRACT

DNA damage is one of the leading causes of various pathological conditions including carcinogenesis. Crotonaldehyde is a 4-carbon unsaturated bifunctional aldehyde which is found ubiquitously and produced both exogenously and endogenously. It reacts with deoxyguanosine and form adducts with DNA. These adducts were detected and found involved in tumor formation in rats treated with crotonaldehyde. In the present study, structural changes in DNA by crotonaldehyde were evaluated by Fourier transform infrared (FTIR) spectroscopy, differential scanning colorimetry (DSC), dynamic light scattering (DLS), high-performance liquid chromatography (HPLC), and atomic force microscopy (AFM). Enhanced binding was observed in cancer autoantibodies with the DNA modified by crotonaldehyde than the native counterpart. Immunological studies revealed enhanced binding of cancer autoantibodies with crotonaldehyde modified DNA, compared to the native form. Furthermore, lymphocyte DNA isolated from cancer patients demonstrated considerable recognition of anti-Cro-DNA IgG as compared to the DNA from healthy individuals. Therefore, we suggest that crotonaldehyde modified DNA presents unique epitopes, that may trigger autoantibody induction in cancer patients.


Subject(s)
Aldehydes/therapeutic use , Autoantibodies/blood , Autoantibodies/immunology , DNA/metabolism , Epitopes/immunology , Neoplasms/drug therapy , Adult , Epitopes/therapeutic use , Female , Humans , Immunoglobulin G/immunology , Male , Middle Aged , Neoplasms/blood , Neoplasms/immunology
9.
Int J Mol Sci ; 15(7): 12323-34, 2014 Jul 11.
Article in English | MEDLINE | ID: mdl-25019344

ABSTRACT

Virgin olive oil (VOO) is credited as being one of many healthful components of the Mediterranean diet. Mediterranean populations experience reduced incidence of chronic inflammatory disease states and VOO is readily consumed as part of an everyday dietary pattern. A phenolic compound contained in VOO, named oleocanthal, shares unique perceptual and anti-inflammatory characteristics with Ibuprofen. Over recent years oleocanthal has become a compound of interest in the search for naturally occurring compounds with pharmacological qualities. Subsequent to its discovery and identification, oleocanthal has been reported to exhibit various modes of action in reducing inflammatory related disease, including joint-degenerative disease, neuro-degenerative disease and specific cancers. Therefore, it is postulated that long term consumption of VOO containing oleocanthal may contribute to the health benefits associated with the Mediterranean dietary pattern. The following paper summarizes the current literature on oleocanthal, in terms of its sensory and pharmacological properties, and also discusses the beneficial, health promoting activities of oleocanthal, in the context of the molecular mechanisms within various models of disease.


Subject(s)
Aldehydes/pharmacology , Anti-Inflammatory Agents/pharmacology , Phenols/pharmacology , Plant Oils/chemistry , Aldehydes/chemistry , Aldehydes/therapeutic use , Animals , Anti-Inflammatory Agents/chemistry , Anti-Inflammatory Agents/therapeutic use , Cyclopentane Monoterpenes , Humans , Olive Oil , Phenols/chemistry , Phenols/therapeutic use
10.
Chem Biol Drug Des ; 103(1): e14371, 2024 01.
Article in English | MEDLINE | ID: mdl-37798397

ABSTRACT

Sickle cell disease (SCD) is the most common genetic disorder, affecting millions of people worldwide. Aromatic aldehydes, which increase the oxygen affinity of human hemoglobin to prevent polymerization of sickle hemoglobin and inhibit red blood cell (RBC) sickling, have been the subject of keen interest for the development of effective treatment against SCD. However, the aldehyde functional group metabolic instability has severly hampered their development, except for voxelotor, which was approved in 2019 for SCD treatment. To improve the metabolic stability of aromatic aldehydes, we designed and synthesized novel molecules by incorporating Michael acceptor reactive centers into the previously clinically studied aromatic aldehyde, 5-hydroxymethylfurfural (5-HMF). Eight such derivatives, referred to as MMA compounds were synthesized and studied for their functional and biological activities. Unlike 5-HMF, which forms Schiff-base interaction with αVal1 nitrogen of hemoglobin, the MMA compounds covalently interacted with ßCys93, as evidenced by reverse-phase HPLC and disulfide exchange reaction, explaining their RBC sickling inhibitory activities, which at 2 mM and 5 mM, range from 0% to 21% and 9% to 64%, respectively. Additionally, the MMA compounds showed a second mechanism of sickling inhibition (12%-41% and 13%-62% at 2 mM and 5 mM, respectively) by directly destabilizing the sickle hemoglobin polymer. In vitro studies demonstrated sustained pharmacologic activities of the compounds compared to 5-HMF. These findings hold promise for advancing SCD therapeutics.


Subject(s)
Anemia, Sickle Cell , Antisickling Agents , Humans , Antisickling Agents/pharmacology , Antisickling Agents/therapeutic use , Hemoglobins/metabolism , Hemoglobins/therapeutic use , Anemia, Sickle Cell/drug therapy , Anemia, Sickle Cell/metabolism , Hemoglobin, Sickle/metabolism , Hemoglobin, Sickle/therapeutic use , Furans , Aldehydes/therapeutic use , Oxygen/metabolism
11.
Nutrients ; 16(16)2024 Aug 18.
Article in English | MEDLINE | ID: mdl-39203892

ABSTRACT

The olive tree (Olea europaea) and olive oil hold significant cultural and historical importance in Europe. The health benefits associated with olive oil consumption have been well documented. This paper explores the mechanisms of the anti-cancer effects of olive oil and olive leaf, focusing on their key bioactive compounds, namely oleocanthal, oleacein, and oleuropein. The chemopreventive potential of oleocanthal, oleacein, and oleuropein is comprehensively examined through this systematic review. We conducted a systematic literature search to identify eligible articles from Scopus, PubMed, and Web of Science databases published up to 10 October 2023. Among 4037 identified articles, there were 88 eligible articles describing mechanisms of chemopreventive effects of oleocanthal, oleacein, and oleuropein. These compounds have the ability to inhibit cell proliferation, induce cell death (apoptosis, autophagy, and necrosis), inhibit angiogenesis, suppress tumor metastasis, and modulate cancer-associated signalling pathways. Additionally, oleocanthal and oleuropein were also reported to disrupt redox hemostasis. This review provides insights into the chemopreventive mechanisms of O. europaea-derived secoiridoids, shedding light on their role in chemoprevention. The bioactivities summarized in the paper support the epidemiological evidence demonstrating a negative correlation between olive oil consumption and cancer risk. Furthermore, the mapped and summarized secondary signalling pathways may provide information to elucidate new synergies with other chemopreventive agents to complement chemotherapies and develop novel nutrition-based anti-cancer approaches.


Subject(s)
Aldehydes , Cyclopentane Monoterpenes , Iridoid Glucosides , Neoplasms , Olea , Olive Oil , Phenols , Animals , Humans , Aldehydes/pharmacology , Aldehydes/therapeutic use , Anticarcinogenic Agents/pharmacology , Anticarcinogenic Agents/therapeutic use , Antineoplastic Agents, Phytogenic/pharmacology , Antineoplastic Agents, Phytogenic/therapeutic use , Apoptosis/drug effects , Cell Proliferation/drug effects , Cyclopentane Monoterpenes/pharmacology , Cyclopentane Monoterpenes/therapeutic use , Iridoid Glucosides/pharmacology , Iridoid Glucosides/therapeutic use , Neoplasms/drug therapy , Neoplasms/prevention & control , Olea/chemistry , Olive Oil/chemistry , Olive Oil/therapeutic use , Phenols/pharmacology , Phenols/therapeutic use , Plant Leaves/chemistry
12.
J Neuroinflammation ; 10: 2, 2013 Jan 05.
Article in English | MEDLINE | ID: mdl-23289709

ABSTRACT

BACKGROUND: Alzheimer's disease (AD) is pathologically characterized by excessive accumulation of amyloid-beta (Aß) fibrils within the brain and activation of astrocytes and microglial cells. In this study, we examined anti-inflammatory and anti-amyloidogenic effects of 2,4-bis(p-hydroxyphenyl)-2-butenal (HPB242), an anti-inflammatory compound produced by the tyrosine-fructose Maillard reaction. METHODS: 12-month-old Tg2576 mice were treated with HPB242 (5 mg/kg) for 1 month and then cognitive function was assessed by the Morris water maze test and passive avoidance test. In addition, western blot analysis, Gel electromobility shift assay, immunostaining, immunofluorescence staining, ELISA and enzyme activity assays were used to examine the degree of Aß deposition in the brains of Tg2576 mice. The Morris water maze task was analyzed using two-way ANOVA with repeated measures. Otherwise were analyzed by one-way ANOVA followed by Dunnett's post hoc test. RESULTS: Treatment of HPB242 (5 mg/kg for 1 month) significantly attenuated cognitive impairments in Tg2576 transgenic mice. HPB242 also prevented amyloidogenesis in Tg2576 transgenic mice brains. This can be evidenced by Aß accumulation, BACE1, APP and C99 expression and ß-secretase activity. In addition, HPB242 suppresses the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) as well as activation of astrocytes and microglial cells. Furthermore, activation of nuclear factor-kappaB (NF-κB) and signal transducer and activator of transcription 1/3 (STAT1/3) in the brain was potently inhibited by HPB242. CONCLUSIONS: Thus, these results suggest that HPB242 might be useful to intervene in development or progression of neurodegeneration in AD through its anti-inflammatory and anti-amyloidogenic effects.


Subject(s)
Aldehydes/therapeutic use , Alzheimer Disease/drug therapy , Amyloid beta-Peptides/antagonists & inhibitors , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Disease Models, Animal , Peptide Fragments/antagonists & inhibitors , Phenols/therapeutic use , Plaque, Amyloid/drug therapy , Alzheimer Disease/metabolism , Alzheimer Disease/pathology , Amyloid beta-Peptides/metabolism , Animals , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Cricetinae , Humans , Maze Learning/drug effects , Maze Learning/physiology , Mice , Mice, Transgenic , Peptide Fragments/metabolism , Plaque, Amyloid/pathology
13.
Pharm Biol ; 51(9): 1144-9, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23795810

ABSTRACT

CONTEXT: Citronellal is a monoterpene present in the oil of many species, including Cymbopogon winterianus Jowitt (Poaceae). OBJECTIVE: The present study investigated the effect of citronellal on inflammatory nociception induced by different stimuli and examined the involvement of the NO-cGMP-ATP-sensitive K⁺ channel pathway. MATERIALS AND METHODS: We used male Swiss mice (n = 6 per group) that were treated intraperitoneally with citronellal (25, 50 or 100 mg/kg) 0.5 h after the subplantar injection of 20 µl of carrageenan (CG; 300 µg/paw), tumor necrosis factor-α (TNF-α; 100 pg/paw), prostaglandin E2 (PGE2; 100 ng/paw) or dopamine (DA; 30 µg/paw). The mechanical nociception was evaluated at 0.5, 1, 2 and 3 h after the injection of the agents, using a digital analgesimeter (von Frey). The effects of citronellal were also evaluated in the presence of L-NAME (30 mg/kg) or glibenclamide (5 mg/kg). RESULTS: At all times, citronellal in all doses inhibited the development of mechanical nociception induced by CG (p < 0.001 and p < 0.01) and TNF-α (p < 0.001, p < 0.01, and p < 0.05). The citronellal was able to increase the pain threshold in the DA test (p < 0.001, p < 0.01, and p < 0.05) and in the PGE2 test at all times (p < 0.001 and p < 0.05). L-NAME and glibenclamide reversed the antinociceptive effects of the citronellal at higher doses in the PGE2 test. DISCUSSION AND CONCLUSION: These data suggest that citronellal attenuated mechanical nociception, mediated in part by the NO-cGMP-ATP-sensitive K⁺ channel pathway.


Subject(s)
Aldehydes/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Cyclic GMP/metabolism , Disease Models, Animal , KATP Channels/metabolism , Monoterpenes/therapeutic use , Nitric Oxide/metabolism , Nociceptive Pain/prevention & control , Acyclic Monoterpenes , Aldehydes/administration & dosage , Aldehydes/antagonists & inhibitors , Animals , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Cyclic GMP/antagonists & inhibitors , Cymbopogon/chemistry , Dose-Response Relationship, Drug , Enzyme Inhibitors/pharmacology , Glyburide/pharmacology , Indonesia , KATP Channels/antagonists & inhibitors , Male , Mice , Monoterpenes/administration & dosage , Monoterpenes/antagonists & inhibitors , NG-Nitroarginine Methyl Ester/pharmacology , Nitric Oxide/antagonists & inhibitors , Nitric Oxide Synthase/antagonists & inhibitors , Nitric Oxide Synthase/metabolism , Nociceptive Pain/immunology , Nociceptive Pain/metabolism , Oils, Volatile/chemistry , Pain Threshold/drug effects , Plant Oils/chemistry , Potassium Channel Blockers/pharmacology , Signal Transduction/drug effects
14.
Biol Res ; 44(4): 363-8, 2011.
Article in English | MEDLINE | ID: mdl-22446600

ABSTRACT

The anti-inflammatory and redox protective effects of the citronellal (CT) were evaluated using in vivo and in vitro tests. Intraperitoneal (i.p.) administration of CT (50, 100, and 200 mg/kg) inhibited (p < 0.05) the carrageenan-induced leukocyte migration to the peritoneal cavity. Additionally, the carrageenan- and arachidonic acid-induced rat hind paw edema was significantly inhibited (p < 0.05) by i.p. administration of 100 and 200 mg/kg of the compound. When the redox activity was evaluated, CT (200 mg/kg) significantly reduced hepatic lipoperoxidation (p < 0.001), as well as oxidation of plasmatic (p < 0.05) and hepatic (p < 0.01) proteins. The results of the present study support the hypothesis that CT possesses anti-inflammatory and redox protective activities. It is suggested that its effects are associated with the inhibition of the enzymes in the arachidonic acid pathway, which prevent cell migration by inhibiting leukotriene production, edema formation and the increase of reactive oxygen species in tissues. Therefore, CT is of potential benefit to manage inflammatory disorders and correlated damages caused by oxidant agents.


Subject(s)
Aldehydes/therapeutic use , Anti-Inflammatory Agents/therapeutic use , Edema/drug therapy , Monoterpenes/therapeutic use , Oxidative Stress/drug effects , Acyclic Monoterpenes , Animals , Arachidonic Acid , Carrageenan , Edema/chemically induced , Hindlimb , Male , Oxidation-Reduction , Rats , Rats, Wistar
15.
Handb Exp Pharmacol ; 205: 317-37, 2011.
Article in English | MEDLINE | ID: mdl-21882119

ABSTRACT

Immunizations belong to the most successful interventions in medicine. Like other drugs, vaccines undergo long periods of pre-clinical development, followed by careful clinical testing through study Phases I, II, and III before they receive licensure. A successful candidate vaccine will move on to be an investigational vaccine to undergo three phases of pre-licensure clinical trials in a stepwise fashion before it can be considered for approval, followed by an optional fourth phase of post-marketing assessment. The overall risk-benefit assessment of a candidate vaccine is very critical in making the licensure decision for regulatory authorities, supported by their scientific committees. It includes analyses of immunogenicity, efficacy, reactogenicity or tolerability, and safety of the vaccine. Public trust in vaccines is a key to the success of immunization programs worldwide. Maintaining this trust requires knowledge of the benefits and scientific understanding of real or perceived risks of immunizations. Under certain circumstances, pre- or post-exposure passive immunization can be achieved by administration of immunoglobulines. In terms of prevention of infectious diseases, disinfection can be applied to reduce the risk of transmission of pathogens from patient to patient, health-care workers to patients, patients to health-care workers, and objects or medical devices to patients.


Subject(s)
Communicable Disease Control/methods , Disinfectants/therapeutic use , Vaccination/methods , Alcohols/therapeutic use , Aldehydes/therapeutic use , Clinical Trials as Topic/methods , Drug Approval/legislation & jurisprudence , Drug Approval/methods , Drug Evaluation, Preclinical/methods , Drug Evaluation, Preclinical/standards , Europe , Humans , Immunization, Passive/methods , Oxidants/therapeutic use , Pediatrics/legislation & jurisprudence , Pediatrics/methods , Phenols/therapeutic use , Povidone-Iodine/therapeutic use , Product Surveillance, Postmarketing , Quaternary Ammonium Compounds/therapeutic use , United States , Vaccination/adverse effects , Vaccines/adverse effects , Vaccines/therapeutic use
16.
Am J Ophthalmol ; 230: 60-67, 2021 10.
Article in English | MEDLINE | ID: mdl-33945820

ABSTRACT

PURPOSE: To assess the post-acute activity and clinical utility of reproxalap, a novel reactive aldehyde species (RASP) inhibitor, versus vehicle in patients with seasonal allergic conjunctivitis. DESIGN: Parallel-group, double-masked, randomized Phase 3 trial. METHODS: Two topical ocular reproxalap concentrations (0.25% and 0.5%) were evaluated versus vehicle in patients with allergic conjunctivitis randomized 1:1:1 and treated with test article 10 minutes prior to conjunctival seasonal allergen challenge. The primary endpoint was area under the post-acute ocular itching score (range = 0-4) curve from 10 to 60 minutes after challenge. The key secondary endpoint was the proportion of subjects with ≥2 points improvement from their peak ocular itching score at baseline. RESULTS: A total of 318 patients were randomized at 11 US sites. Both concentrations of reproxalap (0.25% and 0.5%) achieved the primary endpoint (P < .0001 and P = .003, respectively) and the key secondary endpoint (P = .0005 and P = .02, respectively). Time to complete resolution of ocular itching was statistically faster for both reproxalap concentrations than for vehicle (P < .0001 and P = .001, respectively). No safety or tolerability concerns were noted. The most common adverse event was mild and transient instillation site irritation. CONCLUSION: Reproxalap was effective at reducing ocular itching in patients with allergic conjunctivitis. Reproxalap activity was clinically relevant, as assessed by responder-based and distributional analyses. ALLEVIATE represents one of the first allergic conjunctivitis Phase 3 trials of a novel mechanism of action in decades, and is unique among conjunctival allergen challenge trials in assessing clinical relevance with standard and validated techniques.


Subject(s)
Anti-Allergic Agents , Conjunctivitis, Allergic , Aldehydes/therapeutic use , Allergens/therapeutic use , Aminoquinolines/therapeutic use , Anti-Allergic Agents/therapeutic use , Conjunctivitis, Allergic/diagnosis , Conjunctivitis, Allergic/drug therapy , Double-Blind Method , Humans , Ophthalmic Solutions/therapeutic use
17.
Naunyn Schmiedebergs Arch Pharmacol ; 394(10): 2033-2047, 2021 10.
Article in English | MEDLINE | ID: mdl-34254154

ABSTRACT

Gabapentinoids are effective drugs in most animal models of pain and inflammation with variable effects in humans. The current study evaluated the pharmacological activity of gabapentin (GBP) and its salicylaldehyde derivative (gabapentsal; [2-(1-(((2-hydroxybenzylidene) amino) methyl) cyclohexyl) acetic acid]; GPS) in well-established mouse models of nociceptive pain, inflammatory edema, and pyrexia at doses of 25-100 mg/kg. GPS allayed tonic visceral pain as reflected by acetic acid-induced nociception and it also diminished thermally induced nociception as a mimic of phasic thermal pain. Antagonism of GPS-induced antinociceptive activities by naloxone (NLX, 1.0 mg/kg, subcutaneously, s.c), beta-funaltrexamine (ß-FNT, 5.0 mg/kg, s.c), naltrindole (NT, 1.0 mg/kg, s.c), and nor-binaltorphimine (NOR-BNI, 5.0 mg/kg, s.c), and pentylenetetrazole (PTZ-15 mg/kg, intraperitoneally, i.p) implicated an involvement of both opioidergic and GABAergic mechanisms. Tail immersion test was conducted in order to delineate the mechanistic insights of antinociceptive response. Inflammatory edema induced by carrageenan, histamine, or serotonin was also effectively reversed by GPS in a fashion analogous to aspirin (150 mg/kg, i.p), chlorpheniramine (1.0 mg/kg, i.p), and mianserin (1.0 mg/kg, i.p), respectively. Additionally, yeast-induced pyrexia was decreased by GPS in a comparable manner to acetaminophen (50 mg/kg, i.p). These observations suggest that GPS possesses ameliorative properties in tonic, phasic, and tail immersion tests of nociception via opioidergic and GABAergic mechanisms, curbs inflammatory edema, and is antipyretic in nature.


Subject(s)
Aldehydes/therapeutic use , Analgesics/therapeutic use , Anti-Inflammatory Agents/therapeutic use , Antipyretics/therapeutic use , Edema/drug therapy , Fever/drug therapy , Gabapentin/analogs & derivatives , Gabapentin/therapeutic use , Nociceptive Pain/drug therapy , Animals , Carrageenan , Disease Models, Animal , Edema/chemically induced , Histamine , Male , Mice, Inbred BALB C , Saccharomyces cerevisiae , Serotonin
18.
J Neurosci ; 29(3): 610-9, 2009 Jan 21.
Article in English | MEDLINE | ID: mdl-19158288

ABSTRACT

Amyotrophic lateral sclerosis (ALS), characterized by degeneration of spinal motor neurons, consists of sporadic and familial forms. One cause of familial ALS is missense mutations in the superoxide dismutase 1 (SOD1) gene. Iron accumulation occurs in the CNS of both forms of ALS; however, its contribution to the pathogenesis of ALS is not known. We examined the role of iron in a transgenic mouse line overexpressing the human SOD1(G37R) mutant. We show that multiple mechanisms may underlie the iron accumulation in neurons and glia in SOD1(G37R) transgenic mice. These include dysregulation of proteins involved in iron influx and sensing of intracellular iron; iron accumulation in ventral motor neurons secondary to blockage of anterograde axonal transport; and increased mitochondrial iron load in neurons and glia. We also show that treatment of SOD1(G37R) mice with an iron chelator extends life span by 5 weeks, accompanied by increased survival of spinal motor neurons and improved locomotor function. These data suggest that iron chelator therapy might be useful for the treatment of ALS.


Subject(s)
Amyotrophic Lateral Sclerosis/complications , Amyotrophic Lateral Sclerosis/pathology , Central Nervous System/metabolism , Iron/metabolism , Age Factors , Aldehydes/therapeutic use , Amyotrophic Lateral Sclerosis/drug therapy , Amyotrophic Lateral Sclerosis/genetics , Animals , Body Weight/drug effects , Body Weight/genetics , Cation Transport Proteins/genetics , Cation Transport Proteins/metabolism , Cyclooxygenase 1/genetics , Cyclooxygenase 1/metabolism , Disease Models, Animal , Disease Progression , Ferrozine , Gene Expression Regulation/genetics , Glial Fibrillary Acidic Protein/metabolism , Homeostasis , Hydrazones/therapeutic use , Indoles , Iron Chelating Agents/therapeutic use , Membrane Proteins/genetics , Membrane Proteins/metabolism , Mice , Mice, Inbred C57BL , Mice, Transgenic , Mitochondria/metabolism , Mutation , Phosphopyruvate Hydratase/metabolism , Receptors, Transferrin/genetics , Receptors, Transferrin/metabolism , Sciatic Neuropathy/metabolism , Superoxide Dismutase/genetics
19.
J Mol Cell Cardiol ; 49(4): 576-86, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20685357

ABSTRACT

Reactive oxygen species (ROS) attack polyunsaturated fatty acids of the membrane and trigger lipid peroxidation, which results in the generation of alpha,beta-unsaturated aldehydes, such as 4-hydroxy-2-nonenal (4-HNE). There is compelling evidence that high concentrations of aldehydes are responsible for much of the damage elicited by cardiac ischemia-reperfusion injury, while sublethal concentrations of aldehydes stimulate stress resistance pathways, to achieve cardioprotection. We investigated the mechanism of cardioprotection mediated by 4-HNE. For cultured cardiomyocytes, 4-HNE was cytotoxic at higher concentrations (>or=20 microM) but had no appreciable cytotoxicity at lower concentrations. Notably, a sublethal concentration (5muM) of 4-HNE primed cardiomyocytes to become resistant to cytotoxic concentrations of 4-HNE. 4-HNE induced nuclear translocation of transcription factor NF-E2-related factor 2 (Nrf2), and enhanced the expression of gamma-glutamylcysteine ligase (GCL) and the core subunit of the Xc(-) high-affinity cystine transporter (xCT), thereby increasing 1.45-fold the intracellular GSH levels. Cardiomyocytes treated with either Nrf2-specific siRNA or the GCL inhibitor l-buthionine sulfoximine (BSO) were less tolerant to 4-HNE. Moreover, the cardioprotective effect of 4-HNE pretreatment against subsequent glucose-free anoxia followed by reoxygenation was completely abolished in these cells. Intravenous administration of 4-HNE (4 mg/kg) activated Nrf2 in the heart and increased the intramyocardial GSH content, and consequently improved the functional recovery of the left ventricle following ischemia-reperfusion in Langendorff-perfused hearts. This cardioprotective effect of 4-HNE was not observed for Nrf2-knockout mice. In summary, 4-HNE activates Nrf2-mediated gene expression and stimulates GSH biosynthesis, thereby conferring on cardiomyocytes protection against ischemia-reperfusion injury.


Subject(s)
Aldehydes/therapeutic use , NF-E2-Related Factor 2/metabolism , Reperfusion Injury/prevention & control , Aldehydes/pharmacology , Animals , Blotting, Western , Cell Death/drug effects , Cells, Cultured , Glutathione/metabolism , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Myocytes, Cardiac/cytology , Myocytes, Cardiac/drug effects , NF-E2-Related Factor 2/genetics , Polymerase Chain Reaction , Rats , Rats, Sprague-Dawley , Signal Transduction/drug effects
20.
J Orofac Pain ; 24(3): 305-12, 2010.
Article in English | MEDLINE | ID: mdl-20664833

ABSTRACT

AIMS: To evaluate the antinociceptive effects of citronellal (CTL) on formalin-, capsaicin-, and glutamate-induced orofacial nociception in mice and to investigate whether such effects might involve a change in neural excitability. METHODS: Male mice were pretreated with CTL (50, 100, and 200 mg/kg, ip), morphine (5 mg/kg, ip), or vehicle (distilled water plus one drop of Tween 80 0.2%) before formalin (20 microL, 2%), capsaicin (20 microL, 2.5 microg) or glutamate (40 microL, 25 microM) injection into the right vibrissa. Sciatic nerve recordings were made using the single sucrose gap technique in rats. The data obtained were analyzed by ANOVA followed by Dunnett's test for the behavioral analyses and by the Student t test for CAP evaluation. RESULTS: Pretreatment with CTL was effective in reducing nociceptive face-rubbing behavior in both phases of the formalin test, which was also naloxone-sensitive. CTL produced significantly antinociceptive effect at all doses in the capsaicin- and glutamate- tests. Rota-rod testing indicated that such results were unlikely to be provoked by motor abnormality. Recordings using the single sucrose gap technique revealed that CTL (10 mM) could reduce the excitability of the isolated sciatic nerve through a diminution of the compound action potential amplitude by about 42.4% from control recordings. CONCLUSION: These results suggest that CTL might represent an important tool for management and/or treatment of orofacial pain.


Subject(s)
Aldehydes/therapeutic use , Analgesics/therapeutic use , Capsaicin/adverse effects , Facial Pain/drug therapy , Formaldehyde/adverse effects , Glutamates/adverse effects , Monoterpenes/therapeutic use , Nociceptors/drug effects , Pain/prevention & control , Sensory System Agents/adverse effects , Action Potentials/drug effects , Acyclic Monoterpenes , Animals , Facial Pain/chemically induced , Male , Mice , Morphine/therapeutic use , Motor Activity/drug effects , Narcotics/therapeutic use , Neural Conduction/drug effects , Rats , Rats, Wistar , Sciatic Nerve/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL